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To the Editor, 
Although the definition of nonvalvular atrial fibrillation (NVAF) varies,
1 and 2
 it generally does not 
exclude patients with structural heart disease (SHD), such as certain valve diseases. However, there is 
limited information on the frequency of this association in Spain. The objective of this article was to 
report the prevalence and clinical profile of patients with SHD and well as the prevalence of heart failure 
in a broad Spanish nationwide sample of patients with NVAF. 
Data from the FANTASIIA registry
3
 were used. This registry included 2178 outpatients with NVAF 
who were receiving anticoagulation (according to protocol, the ratio of vitamin K antagonists to direct 
anticoagulants was 4:1). We excluded individuals younger than 18 years, those with prosthetic cardiac 
devices, those with any grade of mitral stenosis, and those with moderate or severe mitral regurgitation. 
Participants were enrolled consecutively between June 1, 2013, and October 15, 2014, in 50 Spanish 
centers selected by the investigators to ensure representation from throughout the country, with the 
primary objective of assessing the effectiveness of anticoagulation in patients with NVAF by type and 
quality of treatment. The diagnoses of SHD were taken from the medical records and included the 
following: coronary artery disease, hypertensive heart disease, dilated cardiomyopathy, hypertrophic 
cardiomyopathy, significant valve disease (aortic valve, tricuspid valve, or pulmonary valve disease of at 
least moderate intensity), and other heart diseases. Patients with coronary artery diseases and other 
concurrent heart diseases were classified as having coronary artery disease. The presence of heart failure 
was recorded independently. Overall, 47.15% of the sample had SHD (Table 1). The most frequent type 
of SHD was coronary artery disease (18.14%), followed by hypertensive heart diseases (11.43%), and 
dilated cardiomyopathy (6.01%). Hypertrophic cardiomyopathy was reported in 2.06% and significant 
valve diseases in 1.79%. Only 34 patients (1.56%) had isolated NVAF (age < 65 years, with no heart 
disease or embolic risk factor). Among patients with SHD, there were fewer women and there was a 
higher rate of cardiovascular risk factors, comorbidities, heart failure, permanent atrial fibrillation, and 
severe symptoms, and greater embolic and hemorrhagic risk. These patients also had worse left 
ventricular ejection fractions and renal function, as well as lower hemoglobin levels. Most of the drug 
classes were more frequently prescribed in patients with SHD, except for angiotensin receptor blockers 
(prescribed with a similar frequency) and antiarrhythmics and direct anticoagulants (prescribed less 
often). Overall, 27.23% of the patients had heart failure, with differential characteristics with respect to 
the sample, similar to patients with SHD, with a few exceptions (Table 2). Studies in Spain have reported 
a prevalence of coronary artery disease of between 10% and 20% in anticoagulated patients with NVAF,
4, 
5 and 6
 a similar prevalence to that reported in our study. The CALIFA registry is the only one of these 
studies to report frequencies of hypertensive heart failure (15.7%) and valve disease (4%) in Spain.
4
 
These frequencies are similar to those reported in our registry (11.4% and 2%, respectively). It is possible 
that exclusion of patients with moderate or severe mitral regurgitation could partly explain this low 
frequency of heart disease. In the case of heart failure, previous studies have reported frequencies 
between 22% and 24%,
4, 5 and 6
 which are similar to those observed in this series. A limitation of the 
present study is that several design features (anticoagulation in the 6 months prior to inclusion, exclusion 
of hospitalized patients, the willingness of the physicians involved in the registry, etc) could have resulted 
in a biased sample, and so extrapolation of our results to the overall population with NVAF should be 
made with caution. Furthermore, classification of heart disease was performed using medical records, 
which, although a true reflection of everyday clinical practice, may have heterogeneous application of 
diagnostic criteria. Nevertheless, our results, obtained in a large Spanish sample of consecutive patients 
with NVAF, suggest that almost half have SHD and more than quarter have heart failure. These patients 
had a different clinical profile to the other patients with NVAF and they received direct anticoagulants 
less frequently. 
Table 1. General Characteristics of the Patients Included in the Study by Presence and Type of Structural Heart Disease 
Variable All No SHD SHD P1 Coronary artery disease HTHD DCM HCM Valve disease Others
a P2 
            
Patients, n 2178 1151 1027 
 
395 249 131 45 39 79 
 
Demographic data 
Age, y 73.78 ± 9.42 73.58 ± 9.23 74 ± 9.62 .239 74.37 ± 8.91 75.86 ± 9.08 69.49 ± 10.55 68.36 ± 11.89 79.1 ± 6.61 73.61 ± 10.21 < .001 
Female sex, % 43.85 48.74 38.36 < .001 26.33 54.22 21.37 24.44 58.97 48.1 < .001 
Cardiovascular risk factors and concurrent disease 
Hypertension 80.39 77.85 83.25 .002 86.33 96.39 63.36 68.89 76.92 74.68 < .001 
Hyperlipidemia 52.3 46.57 58.71 < .001 71.9 50.6 54.2 51.11 28.21 41.77 < .001 
Diabetes mellitus 29.57 22.76 37.2 < .001 44.56 36.55 32.82 13.33 20.51 27.85 < .001 
Current smoker 5 6.08 3.8 .015 3.8 3.21 6.87 4.44 0 3.8 .189 
Exsmoker 32.05 26.76 37.98 < .001 49.87 26.9 48.09 22.22 30.77 26.58 < .001 
COPD/OSA 17.54 14.07 21.42 < .001 22.53 24.1 19.85 15.56 17.95 17.72 < .001 
Renal failure 18.92 13.21 25.32 < .001 29.37 22.09 25.19 13.33 28.21 21.52 < .001 
Liver dysfunction 1.1 1.04 1.17 .779 1.52 0.8 0 0 2.56 2.53 .533 
Previous CVA 17.13 16.42 17.92 .355 20.76 14.46 15.27 20 17.95 16.46 .427 
Modified Charlson comorbidity index 1.14 ± 1.15 0.73 ± 0.92 1.6 ± 1.21 < .001 1.72 ± 1.28 1.46 ± 1.07 1.85 ± 1.15 1.33 ± 1.13 1.46 ± 1.33 1.34 ± 1.15 < .001 
Cardiac history 
Heart failure 27.23 0 57.74 < .001 50.63 56.62 95.89 51.11 41.02 51.89 < .001 
Preserved ejection fraction (>45%) 14.97 0 31.74 < .001 21.77 45.78 7.63 51.11 38.46 44.3 < .001 
Depressed ejection fraction (<45%) 12.26 0 26 
 
28.86 10.84 86.26 0 2.56 7.59 
 
ODAC 24.49 27.91 20.68 
 
20.3 20.88 16.79 17.78 23.08 22.78 
 
  
 AF-related information 
Permanent AFb 49.42 43.94 55.56 < .001 51.65 57.43 64.12 51.11 51.28 67.09 < .001 
EHRA functional class III-IVb 8.06 4.01 12.57 < .001 11.9 13.29 9.16 11.11 20.51 12.66 < .001 
CHADS2scale 2.25 ± 1.25 1.86 ± 1.11 2.69 ± 1.25 < .001 2.78 ± 1.26 2.82 ± 1.19 2.6 ± 1.32 2.11 ± 1.17 2.54 ± 1.25 2.39 ± 1.19 < .001 
CHA2DS2-VASc scale 3.7 ± 1.59 3.23 ± 1.42 4.23 ± 1.62 < .001 4.68 ± 1.57 4.28 ± 1.46 3.53 ± 1.66 3.07 ± 1.54 4.21 ± 1.47 3.71 ± 1.59 < .001 
HAS-BLED scale 2.01 ± 1.05 1.89 ± 0.96 2.14 ± 1.11 < .001 2.39 ± 1.15 2.15 ± 0.98 1.72 ± 1.15 1.6 ± 1.12 2.28 ± 1.17 1.86 ± 1 < .001 
Examination and diagnostic procedures at initial visit 
Left bundle branch block 7.25 3.55 11.37 < .001 11.28 8.13 23.62 11.11 8.11 7.69 < .001 
Ejection fraction, % 58.72 ± 11.09 61.8 ± 7.28 55.34 ± 13.35 < .001 52.57 ± 14.04 60.4 ± 9.59 42.6 ± 13.53 65.91 ± 6.98 61.51 ± 6.99 60.92 ± 7.92 < .001 
Hemoglobin, g/dL 13.66 ± 1.71 13.82 ± 1.65 13.48 ± 1.75 < .001 13.49 ± 1.76 13.49 ± 1.6 13.78 ± 1.74 14.26 ± 1.61 12.34 ± 1.81 13.27 ± 1.81 < .001 
Pharmacological therapy 
Diuretics 57.38 47.33 68.59 < .001 61.93 75.5 77.86 60 64.1 75.95 < .001 
Aldosterone antagonist 13.88 6.56 22.05 < .001 21.57 17.67 51.91 13.33 10.26 15.19 < .001 
ACEI 31.18 24.06 39.12 < .001 42.64 33.33 57.25 26.67 20.51 35.44 < .001 
ARB 40.13 39.98 40.29 .883 39.34 53.01 29.01 33.33 20.51 39.24 < .001 
Statins 54.57 45.58 64.59 < .001 87.82 52.21 55.73 46.67 35.9 40.51 < .001 
Antiplatelet agents 10.42 4.46 17.07 < .001 39.09 2.41 4.58 0 7.69 1.27 < .001 
Beta-blockers 60.29 52.06 69.46 < .001 72.59 63.45 85.5 82.22 48.72 51.9 < .001 
Digoxin 18.04 14.26 22.24 < .001 17.51 19.68 41.22 20 25.64 24.05 < .001 
Calcium antagonists 
Dihydropyridines 13.65 12.95 14.44 
.003 
17.51 18.07 3.82 8.89 15.38 8.86 
< .001 Verapamil 2.4 2.71 2.05 1.02 3.21 0.76 6.67 0 2.53 
Diltiazem 8.03 9.97 5.85 7.11 6.43 4.58 2.22 7.69 5.06 
Antiarrhythmics 24.82 28.35 20.88 < .001 19.8 22.49 16.79 37.78 20.51 13.92 < .001 
VKA 75.51 72.09 79.32 
< .001 
79.7 79.12 83.21 82.22 76.92 77.22 
.006 
ODAC 24.49 27.91 20.68 20.3 20.88 16.79 17.78 23.08 22.78 




ACEI, angiotensin converting enzyme inhibitor; AF, atrial fibrillation; ARB, angiotensin receptor blocker; COPD/OSA, chronic obstructive pulmonary diseases/obstructive sleep apnea syndrome; CVA, cerebrovascular 
accident; DCM, dilated cardiomyopathy; EHRA, European Heart Rhythm Association; HCM, hypertrophic cardiomyopathy; HTHD, hypertensive heart disease; ODAC, oral direct anticoagulants; SHD, structural heart 
disease; VKA, vitamin K antagonist. P1, comparison between patients with SHD and without SHD (Mann-Whitney test for continuous variables and chi-square test for categorical variables); P2, comparison between 
patients without SHD, coronary artery diseases, HTHD, DCM, HCM, valve diseases, and others (Kruskal-Wallis test for continuous variables and chi-square test for categorical variables). 
a Congestive heart disease, congenital heart disease, pericardial disease, others. 
b According to the European Society of Cardiology.1 
c Flecainide, propafenone, amiodarone, dronedarone, or sotalol. 
Quantitative data expressed as mean ± standard deviation and qualitative data as percentages. 
Table 2. General Characteristics of the Patients Included in the Study by Presence and Type of Heart Failure 
Variable All Without HF With HF P1 HF conserved HF impaired P2 
        





 Age, y 73.78 ± 9.42 73.7 ± 9.15 73.99 ± 10.1 .541 75.42 ± 9.84 72.23 ± 10.15 < .001 
 Female sex 43.85 45.68 38.95 .005 53.07 21.72 < .001 
Cardiovascular risk factors and concurrent disease 
 Hypertension 80.39 79.87 81.79 .317 88.04 74.16 < .001 
 Hyperlipidemia 52.3 49.15 60.71 < .001 55.21 67.42 .003 
 Diabetes mellitus 29.57 25.3 40.98 < .001 44.79 36.33 .044 
 Current smoker 5 5.43 3.88 .14 2.45 5.62 .055 
 Exsmoker 32.05 29.38 39.96 < .001 29.45 52.81 < .001 
 COPD/OSA 17.54 15.33 23.44 < .001 23.01 23.97 .846 
 Renal failure 18.92 14.64 30.35 < .001 27.61 33.71 .127 
 Liver dysfunction 1.1 1.14 1.01 .805 0.92 1.12 1 
 Previous CVA 17.13 16.85 17.88 .57 15.64 20.6 .132 
 Modified Charlson comorbidity index 1.14 ± 1.15 0.78 ± 0.94 2.11 ± 1.12 < .001 2.11 ± 1.07 2.11 ± 1.18 1 
  
Cardiac history 




 Coronary artery disease 18.91 12.62 36.76 30.39 43.68 
 Hypertensive heart diseases 11.92 6.99 25.92 40.28 10.34 
 Dilated cardiomyopathy 6.27 0.52 22.61 3.53 43.30 
 Hypertrophic cardiomyopathy 2.15 1.42 4.23 8.13 0.00 
 Valve disease 1.87 1.49 2.94 5.30 0.38 
 Other heart diseasesa 3.78 2.46 7.54 12.37 2.30 
AF-related information 
 Permanent AFb 49.42 45.13 60.88 < .001 60.12 61.8 .827 
 EHRA functional class III-IVb 8.06 4.56 17.37 < .001 18.09 16.47 .332 
 CHADS2scale 2.25 ± 1.25 1.92 ± 1.1 3.12 ± 1.2 < .001 3.24 ± 1.09 2.99 ± 1.3 .013 
 CHA2DS2-VASc scale 3.7 ± 1.59 3.35 ± 1.43 4.63 ± 1.65 < .001 4.87 ± 1.49 4.34 ± 1.77 < .001 
 HAS-BLED scale 2.01 ± 1.05 1.93 ± 1 2.2 ± 1.14 < .001 2.24 ± 1.03 2.15 ± 1.25 .346 
Examination and diagnostic procedures at initial visit 
 Complete left bundle branch block 7.25 3.8 16.47 < .001 9.97 24.43 < .001 
 Ejection fraction, % 58.72 ± 11.09 61.68 ± 7.65 51.17 ± 14.45 < .001 60.29 ± 8.3 40.14 ± 12.48 < .001 
 Hemoglobin, g/dL 13.66 ± 1.71 13.75 ± 1.67 13.41 ± 1.78 < .001 13.2 ± 1.75 13.67 ± 1.78 .001 
Pharmacological therapy 
 Diuretics 57.38 49.46 78.41 < .001 78.22 78.65 .920 
 Aldosterone antagonist 13.88 6.73 32.88 < .001 19.63 49.06 < .001 
 ACEI 31.18 26.29 44.18 < .001 36.2 53.93 < .001 
 ARB 40.13 40.51 39.12 .558 42.94 34.46 .042 
 Statins 54.57 51.49 62.73 < .001 58.28 68.16 .013 
 Antiplatelet agents 10.42 8.51 15.51 < .001 13.5 17.98 .139 
 Beta-blockers 60.29 54.6 75.38 < .001 69.02 83.15 < .001 
 Digoxin 18.04 14.41 27.66 < .001 21.78 34.83 < .001 
  
 Calcium antagonists 
  Dihydropyridines 13.65 14.41 11.64 
.006 
15.34 7.12 
.001   Verapamil 2.4 2.6 1.85 2.15 1.5 
  Diltiazem 8.03 8.95 5.56 7.36 3.37 
 Antiarrhythmicsc 24.82 26.86 19.39 < .001 21.47 16.85 .175 




 ODAC 24.49 26.54 19.06 19.94 17.98 
        
 
ACEI, angiotensin converting enzyme inhibitor; AF, atrial fibrillation; ARB, angiotensin receptor blocker; COPD/OSA, chronic obstructive pulmonary diseases/obstructive sleep apnea syndrome; CVA, cerebrovascular 
accident; EHRA, European Heart Rhythm Association; HF, heart failure; ODAC, oral direct anticoagulants; SHD, structural heart disease; VKA, vitamin K antagonist. P1, comparison between patients with HF and 
without HF (Mann-Whitney test for continuous variables and chi-square test for categorical variables); P2, comparison between patients with HF and conserved systolic function and patients with HF and depressed 
systolic function (Kruskal-Wallis test for continuous variables and chi-square test for categorical variables). 
a Congestive heart diseases, congenital heart diseases, pericardial disease, others. 
b According to the European Society of Cardiology.1 
c Flecainide, propafenone, amiodarone, dronedarone, or sotalol. 
Quantitative data expressed as mean ± standard deviation and qualitative data as percentages. 
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